tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PTGX Stock Latest News

Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
RatingsProtagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
7d ago
PTGX
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
PremiumRatings
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
8d ago
PTGX
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
PremiumRatings
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
8d ago
PTGX
Protagonist Therapeutics: Promising Obesity Program and Strategic Partnerships Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Promising Obesity Program and Strategic Partnerships Drive Buy Rating
8d ago
PTGX
Protagonist Therapeutics’ Innovative Oral Obesity Candidate PN477 Earns Buy Rating from Analyst Geoff Meacham
PremiumRatings
Protagonist Therapeutics’ Innovative Oral Obesity Candidate PN477 Earns Buy Rating from Analyst Geoff Meacham
8d ago
PTGX
Protagonist Therapeutics Stockholders Approve Key Proposals
PremiumCompany AnnouncementsProtagonist Therapeutics Stockholders Approve Key Proposals
12d ago
8K
PTGX
Protagonist Therapeutics initiated with a Buy at Citi
Premium
The Fly
Protagonist Therapeutics initiated with a Buy at Citi
22d ago
PTGX
Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
Premium
Ratings
Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
1M ago
PTGX
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
PremiumRatings
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
1M ago
PTGX
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
PremiumThe Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
1M ago
TAK
PTGX
Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
2M ago
PTGX
Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study
PremiumThe Fly
Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study
2M ago
PTGX
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating
PremiumRatingsProtagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating
2M ago
PTGX
Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships
Premium
Ratings
Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships
2M ago
PTGX
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
Premium
Ratings
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
2M ago
PTGX
Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c
PremiumThe Fly
Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c
2M ago
PTGX
Is PTGX a Buy, Before Earnings?
PremiumPre-Earnings
Is PTGX a Buy, Before Earnings?
2M ago
PTGX
Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
PremiumRatings
Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
3M ago
PTGX
Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating
3M ago
PTGX
Promising Prospects for Protagonist Therapeutics: Buy Rating Backed by Strong Icotrokinra Results and Pipeline Potential
PremiumRatingsPromising Prospects for Protagonist Therapeutics: Buy Rating Backed by Strong Icotrokinra Results and Pipeline Potential
3M ago
PTGX
Protagonist announces data from subgroup analysis in ICONIC-LEAD study
Premium
The Fly
Protagonist announces data from subgroup analysis in ICONIC-LEAD study
3M ago
PTGX
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song
Premium
Ratings
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song
3M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >